<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04149405</url>
  </required_header>
  <id_info>
    <org_study_id>KAEK 2016/100</org_study_id>
    <nct_id>NCT04149405</nct_id>
  </id_info>
  <brief_title>Alterations of GCF Levels of Sclerostin and DKK-1 in Postmenopausal Osteoporosis</brief_title>
  <official_title>Investigation of the Effects of Bisphosphonate on the Gingival Crevicular Fluid Levels of Sclerostin and the DKK-1 in Individuals With Postmenopausal Osteoporosis With Periodontal Changes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ondokuz Mayıs University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ondokuz Mayıs University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Symptoms of periodontal disease are tissue destruction and destruction of the alveolar bone
      which supports the tooth. Wnt way (wingless-type MMTV integration site family) plays a role
      in the regulation of bone homeostasis in periodontal disease-induced bone resorption. The Wnt
      / β-catenin signal is controlled by physiological antagonists, including dickkopf released
      from osteocytes-associated protein 1 (DKK-1) and sclerostin (SOST). Thus, Wnt inhibitors SOST
      and DKK-1 affect bone mass changes. Bisphosphonates used in osteoporous treatment are
      selective inhibitors of bone resorption. In the serum of postmenopausal osteoporotic women
      treated with bisphosphonate, short-term and decreased DKK-1 level during the treatment, and
      increased SOST in the late period were reported. Increased bone formation after
      bisphosphonate treatment in postmenopausal osteoporotic patients has been associated with
      increased serum SOST level. The aim of our study is to investigate the effect of
      bisphosphonate in patients with post-menopausal osteoporosis on the bone demolition
      metabolism in periodontally healthy and periodontally diseased tooth regions and gingival
      health with the clinical data by investigating the SOST and DDK-1 molecules that play role in
      bone destruction mechanism.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aims to reveal the effect of initial periodontal treatment together with
      bisphosphonate on sclerostin (SOST) and dickkopf-related protein-1 (DKK-1) in gingival
      crevicular fluid (GCF) of patients with osteoporosis.

      Clinical recordings and GCF were obtained from postmenopausal women; with chronic
      periodontitis and those using bisphosphonate (Group A, n=12), with chronic periodontitis and
      otherwise healthy (Group B, n=10), without chronic periodontitis and those using
      bisphosphonate (Group C, n=11), systemically and periodontally healthy controls (Group D,
      n=10) at the baseline.

      GCF sampling were recorded and repeated at the 6th and 12th months in Group A, B and C. SOST
      and DKK-1 values were measured by ELISA.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2016</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">June 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>levels of sclerostin (SOST) and dickkopf-related protein-1 (DKK-1) in gingival crevicular fluid</measure>
    <time_frame>12 months</time_frame>
    <description>changes in sclerostin (SOST) and dickkopf-related protein-1 (DKK-1) in gingival crevicular fluid from baseline to 12 months</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Postmenopausal Osteoporosis</condition>
  <condition>Periodontitis</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>scaling and root planning, bisphosphonate therapy (zoledronic acid)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>scaling and root planning, no bisphosphonate therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>scaling and root planning and bisphosphonate therapy (zoledronic acid)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>no scaling and root planning no bisphosphonate therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>periodontal phase 1 therapy</intervention_name>
    <description>periodontal phase 1 therapy consisted of scaling and root planning with ultrasonic and hand instruments under local anesthesia.</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bisphosphonate therapy</intervention_name>
    <description>bisphosphonate therapy refers to the use of zoledronic acid 5 mg/year (i.v.)</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>GCF</intervention_name>
    <description>gingival crevicular fluid collection by the same investigator.</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_label>Group D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women with T scores less than -2.5 (groups A and C)

          -  The periodontitis patients were selected based on the radiographical evidence of bone
             loss, presence of four or more sites with bleeding on probing (BOP), ≥5 mm pocket
             depth (PD) and ≥6 mm clinical attachment loss (CAL).

          -  The clinically healthy control groups were selected on the basis of no radiographic
             bone loss or CAL and PD≤3 mm.

        Exclusion Criteria:

          -  Any known systemic disease rather than osteoporosis

          -  Smoking

          -  Antibiotic therapy within the last 3 months

          -  Periodontal treatment in the last 6 months
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>51 Years</minimum_age>
    <maximum_age>66 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eser Acarel, PhD,Prof.Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Ondokuz Mayıs University, School of Dentistry, Department of Periodontology</affiliation>
  </overall_official>
  <reference>
    <citation>Hampson G, Edwards S, Conroy S, Blake GM, Fogelman I, Frost ML. The relationship between inhibitors of the Wnt signalling pathway (Dickkopf-1(DKK1) and sclerostin), bone mineral density, vascular calcification and arterial stiffness in post-menopausal women. Bone. 2013 Sep;56(1):42-7. doi: 10.1016/j.bone.2013.05.010. Epub 2013 May 20.</citation>
    <PMID>23702386</PMID>
  </reference>
  <reference>
    <citation>Papapoulos SE, Landman JO, Bijvoet OL, Löwik CW, Valkema R, Pauwels EK, Vermeij P. The use of bisphosphonates in the treatment of osteoporosis. Bone. 1992;13 Suppl 1:S41-9. Review.</citation>
    <PMID>1581119</PMID>
  </reference>
  <reference>
    <citation>Juluri R, Prashanth E, Gopalakrishnan D, Kathariya R, Devanoorkar A, Viswanathan V, Romanos GE. Association of Postmenopausal Osteoporosis and Periodontal Disease: A Double-Blind Case-Control Study. J Int Oral Health. 2015 Sep;7(9):119-23.</citation>
    <PMID>26435630</PMID>
  </reference>
  <results_reference>
    <citation>Lane N, Armitage GC, Loomer P, Hsieh S, Majumdar S, Wang HY, Jeffcoat M, Munoz T. Bisphosphonate therapy improves the outcome of conventional periodontal treatment: results of a 12-month, randomized, placebo-controlled study. J Periodontol. 2005 Jul;76(7):1113-22.</citation>
    <PMID>16018754</PMID>
  </results_reference>
  <results_reference>
    <citation>Balli U, Aydogdu A, Dede FO, Turer CC, Guven B. Gingival Crevicular Fluid Levels of Sclerostin, Osteoprotegerin, and Receptor Activator of Nuclear Factor-κB Ligand in Periodontitis. J Periodontol. 2015 Dec;86(12):1396-404. doi: 10.1902/jop.2015.150270. Epub 2015 Sep 14.</citation>
    <PMID>26367496</PMID>
  </results_reference>
  <results_reference>
    <citation>Napimoga MH, Nametala C, da Silva FL, Miranda TS, Bossonaro JP, Demasi AP, Duarte PM. Involvement of the Wnt-β-catenin signalling antagonists, sclerostin and dickkopf-related protein 1, in chronic periodontitis. J Clin Periodontol. 2014 Jun;41(6):550-7. doi: 10.1111/jcpe.12245.</citation>
    <PMID>24576302</PMID>
  </results_reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>October 12, 2019</study_first_submitted>
  <study_first_submitted_qc>October 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 4, 2019</study_first_posted>
  <last_update_submitted>January 31, 2020</last_update_submitted>
  <last_update_submitted_qc>January 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ondokuz Mayıs University</investigator_affiliation>
    <investigator_full_name>Feyza Otan ÖZDEN</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>sclerostin</keyword>
  <keyword>dickkopf-related protein-1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Osteoporosis, Postmenopausal</mesh_term>
    <mesh_term>Periodontitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diphosphonates</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 1, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/05/NCT04149405/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 1, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/05/NCT04149405/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <pending_results>
    <submitted>June 23, 2020</submitted>
    <returned>July 10, 2020</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

